Image credit: Pat Morgan/Springer Nature Limited

A new era: artificial intelligence and machine learning in prostate cancer

This Review discusses applications of AI in the management of prostate cancer, including diagnostic imaging, surgical interventions, skills training and assessment, digital pathology, and genomics.

Latest Reviews

  • Review Article |

    In this Review, Stabile and colleagues describe the current status of the role of mpMRI in prostate cancer diagnosis, its clinical application and consider its future direction in this disease.

    • Armando Stabile
    • , Francesco Giganti
    • , Andrew B. Rosenkrantz
    • , Samir S. Taneja
    • , Geert Villeirs
    • , Inderbir S. Gill
    • , Clare Allen
    • , Mark Emberton
    • , Caroline M. Moore
    •  & Veeru Kasivisvanathan
  • Review Article |

    In this Review, the authors discuss the molecular and histopathological evidence supporting pathology-driven therapy for advanced bladder cancer, including rare histological subtypes of urothelial carcinoma and non-urothelial carcinomas, and highlight novel molecular taxonomies, relevant biomarkers and promising future therapies.

    • Constantine Alifrangis
    • , Ursula McGovern
    • , Alex Freeman
    • , Thomas Powles
    •  & Mark Linch
  • Review Article |

    This Review by Ricketts and Linehan comprehensively summarizes the findings of The Cancer Genome Atlas analyses of renal cell carcinoma and their clinical implications. The authors highlight unique and shared features of the tumour histological subtypes, their predictive power and their possible utility as therapeutic targets.

    • W. Marston Linehan
    •  & Christopher J. Ricketts
  • Review Article |

    Physical activity has been shown to help erectile dysfunction (ED); however, the use of physical activity to actually treat ED is limited, and explicit guidelines are required. In this Review, Allen describes mechanisms underlying the effect and suggests an exercise treatment programme for ED.

    • Mark S. Allen
  • Review Article |

    Increasing evidence suggests that patients undergoing trimodality bladder-preserving treatment (TMT) and radical cystectomy have comparable outcomes but many continue to be offered surgery. This Review discusses the development of TMT and highlights how technological and biological advances could inform personalized treatment strategies.

    • Yee Pei Song
    • , Alan McWilliam
    • , Peter J. Hoskin
    •  & Ananya Choudhury
  • Review Article |

    Tissue engineering using different cell types and tissue scaffolds offers a promising alternative to substitution urethroplasty, which can be associated with complications, restenosis and poor quality of life. In this Review, the authors describe advances in tissue engineering for urethral replacement and consider the future of the field.

    • Filippo Pederzoli
    • , Gregory Joice
    • , Andrea Salonia
    • , Trinity J. Bivalacqua
    •  & Nikolai A. Sopko

News & Comment

  • News & Views |

    Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

    • Ryan P. Kopp
    •  & Tomasz M. Beer
  • Comment |

    The Internet can be a valuable resource for patients, but it is also a minefield of misinformation and hidden bias. The Urology Care Foundation is attempting to mitigate this flood of inaccurate information by providing high-quality online resources for clinicians, patients and caregivers.

    • Brian Stork
    •  & Stacy Loeb
  • Comment |

    Current clinical issues in testicular germ cell tumour management include limited sensitivity and specificity of conventional biomarkers and, therefore, reliance on serial CT imaging in follow-up monitoring, as well as poor ability to risk stratify patients. Circulating microRNAs are likely to help overcome these challenges and, importantly, could offer cost savings to health-care systems.

    • Matthew J. Murray
    •  & Nicholas Coleman
  • News & Views |

    Immune checkpoint therapy is beneficial for patients with advanced bladder cancer; however, trials generally exclude patients with comorbidities or uncommon histologies. The SAUL trial demonstrates that atezolizumab is safe and efficacious in a patient population that more accurately reflects the real-world scenario, but its benefit might still be limited in historically poorly performing populations.

    • Tyler F. Stewart
    •  & Daniel P. Petrylak